Arcus Dips, But Recovers From Steep Losses, On Merck-Rivaling Cancer Data

Arcus Biosciences touted its Merck-rivaling kidney cancer treatment results Tuesday, but shares took a swim. The post Arcus Dips, But Recovers From Steep Losses, On Merck-Rivaling Cancer Data appeared first on Investor's Business Daily.